{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:39Z","timestamp":1792008099095,"version":"4.4.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T00:00:00Z","timestamp":1284681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00018-010-0518-0","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T17:35:06Z","timestamp":1284658506000},"page":"195-203","source":"Crossref","is-referenced-by-count":156,"title":["Endothelin"],"prefix":"10.1007","volume":"68","author":[{"given":"Yoshifumi","family":"Kawanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya M.","family":"Nauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,17]]},"reference":[{"issue":"2","key":"518_CR1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0163-7258(96)00101-5","volume":"72","author":"GA Gray","year":"1996","unstructured":"Gray GA, Webb DJ (1996) The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 72(2):109\u2013148","journal-title":"Pharmacol Ther"},{"issue":"6163","key":"518_CR2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163):411\u2013415","journal-title":"Nature"},{"key":"518_CR3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","volume":"41","author":"RM Kedzierski","year":"2001","unstructured":"Kedzierski RM, Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851\u2013876","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"25","key":"518_CR4","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1074\/jbc.270.25.15262","volume":"270","author":"N Emoto","year":"1995","unstructured":"Emoto N, Yanagisawa M (1995) Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270(25):15262\u201315268","journal-title":"J Biol Chem"},{"issue":"10","key":"518_CR5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1172\/JCI7447","volume":"105","author":"H Yanagisawa","year":"2000","unstructured":"Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE, Yanagisawa M (2000) Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105(10):1373\u20131382","journal-title":"J Clin Invest"},{"issue":"2","key":"518_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0006-2952(95)02036-5","volume":"51","author":"AJ Turner","year":"1996","unstructured":"Turner AJ, Murphy LJ (1996) Molecular pharmacology of endothelin-converting enzymes. Biochem Pharmacol 51(2):91\u2013102","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"518_CR7","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.4049\/jimmunol.159.4.1987","volume":"159","author":"A Nakano","year":"1997","unstructured":"Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H (1997) Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 159(4):1987\u20131992","journal-title":"J Immunol"},{"issue":"2","key":"518_CR8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/jpet.108.142992","volume":"328","author":"E Simard","year":"2009","unstructured":"Simard E, Jin D, Takai S, Miyazaki M, Brochu I, D\u2019Orleans-Juste P (2009) Chymase-dependent conversion of big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 328(2):540\u2013548","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"518_CR9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bbrc.2005.06.140","volume":"334","author":"J Ortmann","year":"2005","unstructured":"Ortmann J, Nett PC, Celeiro J, Traupe T, Tornillo L, Hofmann-Lehmann R, Haas E, Frank B, Terraciano LM, Barton M (2005) Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem Biophys Res Commun 334(2):689\u2013695","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"518_CR10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/0006-291X(90)91146-J","volume":"168","author":"K Ohnaka","year":"1990","unstructured":"Ohnaka K, Takayanagi R, Yamauchi T, Okazaki H, Ohashi M, Umeda F, Nawata H (1990) Identification and characterization of endothelin converting activity in cultured bovine endothelial cells. Biochem Biophys Res Commun 168(3):1128\u20131136","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"518_CR11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.peptides.2009.11.029","volume":"31","author":"T Matsumoto","year":"2010","unstructured":"Matsumoto T, Ozawa Y, Taguchi K, Kobayashi T, Kamata K (2010) Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction. Peptides 31(2):346\u2013353","journal-title":"Peptides"},{"issue":"3","key":"518_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0092-8674(94)90425-1","volume":"78","author":"D Xu","year":"1994","unstructured":"Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, de Wit D, Yanagisawa M (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78(3):473\u2013485","journal-title":"Cell"},{"issue":"Suppl 1","key":"518_CR13","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/00005344-199800001-00020","volume":"31","author":"R Takayanagi","year":"1998","unstructured":"Takayanagi R, Liu W, Ito T, Ohnaka K, Nawata H (1998) Big endothelin analogues with inhibitory activity on endothelin-converting enzyme-1. J Cardiovasc Pharmacol 31(Suppl 1):S62\u2013S63","journal-title":"J Cardiovasc Pharmacol"},{"issue":"50","key":"518_CR14","doi-asserted-by":"crossref","first-page":"29794","DOI":"10.1074\/jbc.270.50.29794","volume":"270","author":"O Valdenaire","year":"1995","unstructured":"Valdenaire O, Rohrbacher E, Mattei MG (1995) Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem 270(50):29794\u201329798","journal-title":"J Biol Chem"},{"issue":"2","key":"518_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000077132","volume":"41","author":"S Keynan","year":"2004","unstructured":"Keynan S, Khamaisi M, Dahan R, Barnes K, Jackson CD, Turner AJ, Raz I (2004) Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells. J Vasc Res 41(2):131\u2013140","journal-title":"J Vasc Res"},{"issue":"7","key":"518_CR16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/sj.bjc.6604631","volume":"99","author":"LA Lambert","year":"2008","unstructured":"Lambert LA, Whyteside AR, Turner AJ, Usmani BA (2008) Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion. Br J Cancer 99(7):1114\u20131120","journal-title":"Br J Cancer"},{"issue":"4","key":"518_CR17","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1152\/jappl.1996.81.4.1510","volume":"81","author":"J Dupuis","year":"1996","unstructured":"Dupuis J, Goresky CA, Fournier A (1996) Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 81(4):1510\u20131515","journal-title":"J Appl Physiol"},{"issue":"7","key":"518_CR18","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.CIR.94.7.1578","volume":"94","author":"J Dupuis","year":"1996","unstructured":"Dupuis J, Stewart DJ, Cernacek P, Gosselin G (1996) Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94(7):1578\u20131584","journal-title":"Circulation"},{"issue":"1","key":"518_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00126839-199902010-00001","volume":"2","author":"J Goddard","year":"1999","unstructured":"Goddard J, Webb DJ (1999) Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders. Drugs R D 2(1):1\u201312","journal-title":"Drugs R D"},{"issue":"6303","key":"518_CR20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/348730a0","volume":"348","author":"H Arai","year":"1990","unstructured":"Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348(6303):730\u2013732","journal-title":"Nature"},{"issue":"6303","key":"518_CR21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/348732a0","volume":"348","author":"T Sakurai","year":"1990","unstructured":"Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T (1990) Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348(6303):732\u2013735","journal-title":"Nature"},{"issue":"1\u20132","key":"518_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-5793(91)80007-P","volume":"287","author":"K Hosoda","year":"1991","unstructured":"Hosoda K, Nakao K, Hiroshi A, Suga S, Ogawa Y, Mukoyama M, Shirakami G, Saito Y, Nakanishi S, Imura H (1991) Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 287(1\u20132):23\u201326","journal-title":"FEBS Lett"},{"issue":"Suppl 8","key":"518_CR23","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00005344-199322008-00008","volume":"22","author":"AP Davenport","year":"1993","unstructured":"Davenport AP, O\u2019Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR, Ferro A (1993) Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 22(Suppl 8):S22\u2013S25","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"518_CR24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0014-5793(91)80454-B","volume":"282","author":"R Takayanagi","year":"1991","unstructured":"Takayanagi R, Kitazumi K, Takasaki C, Ohnaka K, Aimoto S, Tasaka K, Ohashi M, Nawata H (1991) Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett 282(1):103\u2013106","journal-title":"FEBS Lett"},{"issue":"19","key":"518_CR25","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.102.19.2434","volume":"102","author":"TF Luscher","year":"2000","unstructured":"Luscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102(19):2434\u20132440","journal-title":"Circulation"},{"issue":"Suppl","key":"518_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02718110","volume":"168","author":"TF Luscher","year":"1990","unstructured":"Luscher TF (1990) Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels. Lung 168(Suppl):27\u201334","journal-title":"Lung"},{"issue":"14","key":"518_CR27","doi-asserted-by":"crossref","first-page":"8237","DOI":"10.1016\/S0021-9258(18)83174-X","volume":"264","author":"KK Griendling","year":"1989","unstructured":"Griendling KK, Tsuda T, Alexander RW (1989) Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells. J Biol Chem 264(14):8237\u20138240","journal-title":"J Biol Chem"},{"issue":"3","key":"518_CR28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1172\/JCI114488","volume":"85","author":"Y Takuwa","year":"1990","unstructured":"Takuwa Y, Kasuya Y, Takuwa N, Kudo M, Yanagisawa M, Goto K, Masaki T, Yamashita K (1990) Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells. J Clin Invest 85(3):653\u2013658","journal-title":"J Clin Invest"},{"issue":"2","key":"518_CR29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/endo.132.2.7678793","volume":"132","author":"S Eguchi","year":"1993","unstructured":"Eguchi S, Hirata Y, Imai T, Marumo F (1993) Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature. Endocrinology 132(2):524\u2013529","journal-title":"Endocrinology"},{"key":"518_CR30","doi-asserted-by":"crossref","unstructured":"Eguchi S, Hirata Y, Marumo F 1993 Endothelin subtype B receptors are coupled to adenylate cyclase via inhibitory G protein in cultured bovine endothelial cells. J Cardiovasc Pharmacol 22 (Suppl) 8: S161\u20133","DOI":"10.1097\/00005344-199322008-00043"},{"issue":"Suppl 1","key":"518_CR31","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1097\/01.fjc.0000166252.66486.06","volume":"44","author":"Y Kawanabe","year":"2004","unstructured":"Kawanabe Y, Okamoto Y, Hashimoto N, Masaki T (2004) Molecular mechanisms for activation of voltage-independent Ca2\u00a0+\u00a0channels by endothelin-1\/endothelin-A receptors. J Cardiovasc Pharmacol 44(Suppl 1):S219\u2013S223","journal-title":"J Cardiovasc Pharmacol"},{"issue":"25","key":"518_CR32","doi-asserted-by":"crossref","first-page":"17901","DOI":"10.1074\/jbc.274.25.17901","volume":"274","author":"A Gohla","year":"1999","unstructured":"Gohla A, Offermanns S, Wilkie TM, Schultz G (1999) Differential involvement of Galpha12 and Galpha13 in receptor-mediated stress fiber formation. J Biol Chem 274(25):17901\u201317907","journal-title":"J Biol Chem"},{"issue":"18","key":"518_CR33","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.1016\/S0021-9258(18)42300-9","volume":"267","author":"I Aramori","year":"1992","unstructured":"Aramori I, Nakanishi S (1992) Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J Biol Chem 267(18):12468\u201312474","journal-title":"J Biol Chem"},{"issue":"2","key":"518_CR34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0026-895X(25)13591-8","volume":"43","author":"I Aramori","year":"1993","unstructured":"Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Kojo H, Notsu Y, Ono T, Nakanishi S (1993) Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol 43(2):127\u2013131","journal-title":"Mol Pharmacol"},{"issue":"1","key":"518_CR35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/mol.62.1.75","volume":"62","author":"Y Kawanabe","year":"2002","unstructured":"Kawanabe Y, Okamoto Y, Miwa S, Hashimoto N, Masaki T (2002) Molecular mechanisms for the activation of voltage-independent Ca2\u00a0+\u00a0channels by endothelin-1 in Chinese hamster ovary cells stably expressing human endothelin(A) receptors. Mol Pharmacol 62(1):75\u201380","journal-title":"Mol Pharmacol"},{"issue":"1\u20133","key":"518_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0014-2999(99)00252-6","volume":"375","author":"T Masaki","year":"1999","unstructured":"Masaki T, Miwa S, Sawamura T, Ninomiya H, Okamoto Y (1999) Subcellular mechanisms of endothelin action in vascular system. Eur J Pharmacol 375(1\u20133):133\u2013138","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"518_CR37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1432-1033.1995.tb20236.x","volume":"228","author":"M Takigawa","year":"1995","unstructured":"Takigawa M, Sakurai T, Kasuya Y, Abe Y, Masaki T, Goto K (1995) Molecular identification of guanine-nucleotide-binding regulatory proteins which couple to endothelin receptors. Eur J Biochem 228(1):102\u2013108","journal-title":"Eur J Biochem"},{"issue":"2","key":"518_CR38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/mol.61.2.277","volume":"61","author":"Y Kawanabe","year":"2002","unstructured":"Kawanabe Y, Okamoto Y, Nozaki K, Hashimoto N, Miwa S, Masaki T (2002) Molecular mechanism for endothelin-1-induced stress-fiber formation: analysis of G proteins using a mutant endothelin(A) receptor. Mol Pharmacol 61(2):277\u2013284","journal-title":"Mol Pharmacol"},{"issue":"24","key":"518_CR39","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A Giaid","year":"1993","unstructured":"Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328(24):1732\u20131739","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"518_CR40","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/00005344-199506263-00018","volume":"26","author":"R Corder","year":"1995","unstructured":"Corder R, Carrier M, Khan N, Klemm P, Vane JR (1995) Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Cardiovasc Pharmacol 26(Suppl 3):S56\u2013S58","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"518_CR41","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0735-1097(95)00399-1","volume":"26","author":"M Nootens","year":"1995","unstructured":"Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S (1995) Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26(7):1581\u20131585","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"518_CR42","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","volume":"114","author":"DJ Stewart","year":"1991","unstructured":"Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114(6):464\u2013469","journal-title":"Ann Intern Med"},{"issue":"9","key":"518_CR43","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/hc0902.105719","volume":"105","author":"M Bauer","year":"2002","unstructured":"Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ (2002) Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105(9):1034\u20131036","journal-title":"Circulation"},{"issue":"1","key":"518_CR44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09031936.01.00075501","volume":"18","author":"H Takahashi","year":"2001","unstructured":"Takahashi H, Soma S, Muramatsu M, Oka M, Ienaga H, Fukuchi Y (2001) Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 18(1):5\u201314","journal-title":"Eur Respir J"},{"issue":"9288","key":"518_CR45","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288):1119\u20131123","journal-title":"Lancet"},{"issue":"12","key":"518_CR46","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896\u2013903","journal-title":"N Engl J Med"},{"issue":"4","key":"518_CR47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","volume":"169","author":"RJ Barst","year":"2004","unstructured":"Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR (2004) Sitaxentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169(4):441\u2013447","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"518_CR48","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.CIR.85.2.504","volume":"85","author":"RJ Cody","year":"1992","unstructured":"Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85(2):504\u2013509","journal-title":"Circulation"},{"issue":"3","key":"518_CR49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0735-1097(95)00520-X","volume":"27","author":"R Pacher","year":"1996","unstructured":"Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G (1996) Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27(3):633\u2013641","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"518_CR50","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0735-1097(98)00437-9","volume":"32","author":"M Hulsmann","year":"1998","unstructured":"Hulsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, Berger R, Woloszczuk W, Putz D, Kos T, Berger R, Woloszczuk W, Maurer G, Pacher R (1998) Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32(6):1695\u20131700","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"518_CR51","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.97.8.744","volume":"97","author":"K Ponicke","year":"1998","unstructured":"Ponicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Bohm M, Zerkowski HR, Brodde OE (1998) Endothelin receptors in the failing and nonfailing human heart. Circulation 97(8):744\u2013751","journal-title":"Circulation"},{"issue":"16","key":"518_CR52","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/01.CIR.99.16.2118","volume":"99","author":"O Zolk","year":"1999","unstructured":"Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, Bohm M (1999) Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99(16):2118\u20132123","journal-title":"Circulation"},{"issue":"9123","key":"518_CR53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(05)77807-7","volume":"352","author":"PJ Cowburn","year":"1998","unstructured":"Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, Dargie HJ (1998) Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet 352(9123):201\u2013202","journal-title":"Lancet"},{"issue":"8977","key":"518_CR54","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","volume":"346","author":"W Kiowski","year":"1995","unstructured":"Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346(8977):732\u2013736","journal-title":"Lancet"},{"issue":"7","key":"518_CR55","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0735-1097(00)00649-5","volume":"35","author":"LE Spieker","year":"2000","unstructured":"Spieker LE, Mitrovic V, Noll G, Pacher R, Schulze MR, Muntwyler J, Schalcher C, Kiowski W, Luscher TF (2000) Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 35(7):1745\u20131752","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"518_CR56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0735-1097(03)00556-4","volume":"42","author":"G Torre-Amione","year":"2003","unstructured":"Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I (2003) Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42(1):140\u2013147","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"518_CR57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1388-9842(01)00168-4","volume":"3","author":"G Cotter","year":"2001","unstructured":"Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, Caspi A (2001) Tezosentan (an intravenous endothelin receptor A\/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail 3(4):457\u2013461","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"518_CR58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0735-1097(02)02708-0","volume":"41","author":"E Kaluski","year":"2003","unstructured":"Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G (2003) RITZ-5: randomized intravenous TeZosentan (an endothelin-A\/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41(2):204\u2013210","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"518_CR59","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0735-1097(03)00194-3","volume":"41","author":"CM O\u2019Connor","year":"2003","unstructured":"O\u2019Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M (2003) Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41(9):1452\u20131457","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"518_CR60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0002-8703(02)00127-8","volume":"144","author":"CM O\u2019Connor","year":"2002","unstructured":"O\u2019Connor CM, Gattis WA, Adams KF Jr, Shah MR, Kobrin I, Frey A, Gheorghiade M (2002) Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). Am Heart J 144(4):583\u2013588","journal-title":"Am Heart J"},{"issue":"2","key":"518_CR61","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mhj.2001.116760","volume":"142","author":"C Schalcher","year":"2001","unstructured":"Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W (2001) The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 142(2):340\u2013349","journal-title":"Am Heart J"},{"issue":"2","key":"518_CR62","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1378\/chest.120.2.460","volume":"120","author":"G Torre-Amione","year":"2001","unstructured":"Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C (2001) A pilot safety trial of prolonged (48\u00a0h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 120(2):460\u2013466","journal-title":"Chest"},{"issue":"7","key":"518_CR63","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.CIR.103.7.973","volume":"103","author":"G Torre-Amione","year":"2001","unstructured":"Torre-Amione G, Young JB, Durand J, Bozkurt B, Mann DL, Kobrin I, Pratt CM (2001) Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 103(7):973\u2013980","journal-title":"Circulation"},{"issue":"2\u20133","key":"518_CR64","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","volume":"85","author":"PR Kalra","year":"2002","unstructured":"Kalra PR, Moon JC, Coats AJ (2002) Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85(2\u20133):195\u2013197","journal-title":"Int J Cardiol"},{"issue":"2","key":"518_CR65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1388-9842(99)00022-7","volume":"1","author":"P Mylona","year":"1999","unstructured":"Mylona P, Cleland JG (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure Cardio.net Editorial Team. Eur J Heart Fail 1(2):197\u2013200","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"518_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000048751","volume":"69","author":"S Iwasa","year":"2001","unstructured":"Iwasa S, Fan J, Miyauchi T, Watanabe T (2001) Blockade of endothelin receptors reduces diet-induced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice. Pathobiology 69(1):1\u201310","journal-title":"Pathobiology"},{"issue":"3","key":"518_CR67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7326\/0003-4819-114-3-213","volume":"114","author":"K Yokokawa","year":"1991","unstructured":"Yokokawa K, Tahara H, Kohno M, Murakawa K, Yasunari K, Nakagawa K, Hamada T, Otani S, Yanagisawa M, Takeda T (1991) Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 114(3):213\u2013215","journal-title":"Ann Intern Med"},{"issue":"3","key":"518_CR68","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1006\/bbrc.1997.7394","volume":"238","author":"M Barton","year":"1997","unstructured":"Barton M, Shaw S, d\u2019Uscio LV, Moreau P, Luscher TF (1997) Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238(3):861\u2013865","journal-title":"Biochem Biophys Res Commun"},{"key":"518_CR69","doi-asserted-by":"crossref","unstructured":"Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14(6 Pt 2):83S\u201389S","DOI":"10.1016\/S0895-7061(01)02074-X"},{"issue":"9","key":"518_CR70","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneph0891","volume":"4","author":"M Barton","year":"2008","unstructured":"Barton M (2008) Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 4(9):490\u2013501","journal-title":"Nat Clin Pract Nephrol"},{"issue":"12","key":"518_CR71","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1073\/pnas.96.12.6920","volume":"96","author":"G Caligiuri","year":"1999","unstructured":"Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK (1999) Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci USA 96(12):6920\u20136924","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"518_CR72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11906-000-0064-5","volume":"2","author":"M Barton","year":"2000","unstructured":"Barton M (2000) Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr Hypertens Rep 2(1):84\u201391","journal-title":"Curr Hypertens Rep"},{"issue":"16","key":"518_CR73","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.100.16.1680","volume":"100","author":"S Taddei","year":"1999","unstructured":"Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A (1999) Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 100(16):1680\u20131683","journal-title":"Circulation"},{"issue":"1","key":"518_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3317\/jraas.2002.001","volume":"3","author":"AV Agapitov","year":"2002","unstructured":"Agapitov AV, Haynes WG (2002) Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Sys 3(1):1\u201315","journal-title":"J Renin Angiotensin Aldosterone Sys"},{"issue":"5","key":"518_CR75","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.96.5.1593","volume":"96","author":"P Moreau","year":"1997","unstructured":"Moreau P, d\u2019Uscio LV, Shaw S, Takase H, Barton M, Luscher TF (1997) Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 96(5):1593\u20131597","journal-title":"Circulation"},{"key":"518_CR76","doi-asserted-by":"crossref","unstructured":"Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH, Yanagisawa M, Kumada M (1999) Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 276(4 Pt 2):R1071\u20137","DOI":"10.1152\/ajpregu.1999.276.4.R1071"},{"key":"518_CR77","doi-asserted-by":"crossref","unstructured":"Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ (1999) Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33(1 Pt 2):581\u2013585","DOI":"10.1161\/01.HYP.33.1.581"},{"issue":"10","key":"518_CR78","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1161\/01.CIR.93.10.1860","volume":"93","author":"WG Haynes","year":"1996","unstructured":"Haynes WG, Ferro CJ, O\u2019Kane KP, Somerville D, Lomax CC, Webb DJ (1996) Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93(10):1860\u20131870","journal-title":"Circulation"},{"issue":"8926","key":"518_CR79","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(94)92827-4","volume":"344","author":"WG Haynes","year":"1994","unstructured":"Haynes WG, Webb DJ (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344(8926):852\u2013854","journal-title":"Lancet"},{"issue":"12","key":"518_CR80","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","volume":"338","author":"H Krum","year":"1998","unstructured":"Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension Investigators. N Engl J Med 338(12):784\u2013790","journal-title":"N Engl J Med"},{"issue":"9","key":"518_CR81","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.CIR.0000118499.69469.51","volume":"109","author":"J Goddard","year":"2004","unstructured":"Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ (2004) Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109(9):1186\u20131193","journal-title":"Circulation"},{"issue":"10","key":"518_CR82","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1097\/01.ASN.0000141313.84470.4B","volume":"15","author":"J Goddard","year":"2004","unstructured":"Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ (2004) Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 15(10):2601\u20132610","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"518_CR83","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2005121256","volume":"17","author":"N Dhaun","year":"2006","unstructured":"Dhaun N, Goddard J, Webb DJ (2006) The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17(4):943\u2013955","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"518_CR84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.109.132670","volume":"54","author":"N Dhaun","year":"2009","unstructured":"Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ (2009) Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54(1):113\u2013119","journal-title":"Hypertension"},{"issue":"Suppl 2","key":"518_CR85","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2362.2009.02123.x","volume":"39","author":"A Bhalla","year":"2009","unstructured":"Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M (2009) Endothelin receptor antagonism and cancer. Eur J Clin Invest 39(Suppl 2):74\u201377","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"518_CR86","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1043-2760(98)00094-0","volume":"9","author":"A Bagnato","year":"1998","unstructured":"Bagnato A, Catt KJ (1998) Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 9(9):378\u2013383","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"518_CR87","first-page":"720","volume":"59","author":"A Bagnato","year":"1999","unstructured":"Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG (1999) Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59(3):720\u2013727","journal-title":"Cancer Res"},{"issue":"9","key":"518_CR88","first-page":"1059","volume":"1","author":"A Bagnato","year":"1995","unstructured":"Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ (1995) Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1(9):1059\u20131066","journal-title":"Clin Cancer Res"},{"issue":"24","key":"518_CR89","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1158\/0008-5472.CAN-05-2123","volume":"65","author":"L Rosano","year":"2005","unstructured":"Rosano L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, Bagnato A (2005) Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65(24):11649\u201311657","journal-title":"Cancer Res"},{"issue":"5","key":"518_CR90","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0002-9440(10)64791-8","volume":"157","author":"D Salani","year":"2000","unstructured":"Salani D, Di Castro V, Nicotra MR, Rosano L, Tecce R, Venuti A, Natali PG, Bagnato A (2000) Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157(5):1537\u20131547","journal-title":"Am J Pathol"},{"issue":"17","key":"518_CR91","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-04-2682","volume":"11","author":"AA Jazaeri","year":"2005","unstructured":"Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11(17):6300\u20136310","journal-title":"Clin Cancer Res"},{"issue":"2","key":"518_CR92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-5793(88)80489-7","volume":"238","author":"I Komuro","year":"1988","unstructured":"Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y (1988) Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 238(2):249\u2013252","journal-title":"FEBS Lett"},{"issue":"18","key":"518_CR93","first-page":"5310","volume":"60","author":"F Vacca","year":"2000","unstructured":"Vacca F, Bagnato A, Catt KJ, Tecce R (2000) Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60(18):5310\u20135317","journal-title":"Cancer Res"},{"issue":"14","key":"518_CR94","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1091\/mbc.e09-01-0085","volume":"20","author":"A Pedram","year":"2009","unstructured":"Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER (2009) Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell 20(14):3374\u20133389","journal-title":"Mol Biol Cell"},{"issue":"Suppl 1","key":"518_CR95","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/01.fjc.0000166255.12229.0d","volume":"44","author":"F Spinella","year":"2004","unstructured":"Spinella F, Rosano L, Elia G, Di Castro V, Natali PG, Bagnato A (2004) Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol 44(Suppl 1):S140\u2013S143","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"518_CR96","first-page":"1123","volume":"231","author":"F Spinella","year":"2006","unstructured":"Spinella F, Rosano L, Decandia S, Di Castro V, Albini A, Elia G, Natali PG, Bagnato A (2006) Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med (Maywood) 231(6):1123\u20131127","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"518_CR97","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/14737140.5.3.419","volume":"5","author":"A Jimeno","year":"2005","unstructured":"Jimeno A, Carducci M (2005) Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 5(3):419\u2013427","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"518_CR98","first-page":"1132","volume":"231","author":"L Rosano","year":"2006","unstructured":"Rosano L, Di Castro V, Spinella F, Decandia S, Natali PG, Bagnato A (2006) ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) 231(6):1132\u20131135","journal-title":"Exp Biol Med (Maywood)"},{"issue":"8","key":"518_CR99","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1517\/13543784.17.8.1237","volume":"17","author":"R Warren","year":"2008","unstructured":"Warren R, Liu G (2008) ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs 17(8):1237\u20131245","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"518_CR100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CAD.0b013e328320791c","volume":"20","author":"JW Growcott","year":"2009","unstructured":"Growcott JW (2009) Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 20(2):83\u201388","journal-title":"Anticancer Drugs"},{"issue":"8","key":"518_CR101","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1073\/pnas.0807158106","volume":"106","author":"L Rosano","year":"2009","unstructured":"Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A (2009) Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106(8):2806\u20132811","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"518_CR102","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-07-0151","volume":"6","author":"L Rosano","year":"2007","unstructured":"Rosano L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A (2007) ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 6(7):2003\u20132011","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"518_CR103","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1097\/01.fjc.0000166259.96980.6a","volume":"44","author":"L Rosano","year":"2004","unstructured":"Rosano L, Spinella F, Di Castro V, Natali PG, Bagnato A (2004) Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. J Cardiovasc Pharmacol 44(Suppl 1):S132\u2013S135","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"518_CR104","first-page":"2447","volume":"63","author":"L Rosano","year":"2003","unstructured":"Rosano L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A (2003) Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63(10):2447\u20132453","journal-title":"Cancer Res"},{"issue":"3","key":"518_CR105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/157016107781024082","volume":"5","author":"M Smollich","year":"2007","unstructured":"Smollich M, Wulfing P (2007) The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 5(3):239\u2013248","journal-title":"Curr Vasc Pharmacol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-010-0518-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-010-0518-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-010-0518-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T21:50:50Z","timestamp":1740520250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-010-0518-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,17]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1007\/s00018-010-0518-0","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,17]]}}}